Roivant Sciences Ltd. Common Shares
ROIV · Nasdaq
ROIV · Nasdaq
Roivant Sciences is a biotechnology company whose evidenced activity centers on developing clinical-stage medicines and advancing them through regulatory decisions and commercialization. The supplied coverage identifies mosliciguat, LISRAYA, and batoclimab-related development as important assets or catalysts, but does not provide segment reporting or the contribution of any individual product. Its customers, commercial revenue model, employee count, and operating scale are not stated in the evidence. Reported revenue was $0.0 billion in both FY2025 and FY2026, while net income was negative $0.2 billion and negative $0.3 billion, respectively, indicating that the reported business remained loss-making.
